Adaptimmune Therapeutics (ADAP) Stock Highlights

0.99 | -3.88%

2024-04-18 02:45:05

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, NON-SMALL CELL LUNG CANCER, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.

Statistics

Range Today

0.93 1.04

Volume Today 1.22M

Range 1 Year

0.42 2.05

Volume 1 Year 250.99M

Range 3 Year

0.42 6.86

Volume 3 Year 665.45M

Range 10 Year

0.42 21.57

Volume 10 Year 1.6B

Highlights

Market Capitalization 329.59M (small)

Floating Shares 733.9M

Current Price 0.99

Price To Earnings -2.45

Price To Revenue 26.48

Price To Book 6.67

Earnings Per Share -0.49

Payout Ratio 0%

Performance

Latest -3.88%

1 Month -34%

3 Months +35.62%

6 Months +52.31%

1 Year -27.21%

3 Years -79.8%

5 Years -76.87%

10 Years -94.86%

Benchmarks

Market Capitalization

185 / 377

Gross Profits

245 / 285

Total Revenue

107 / 309

Total Rank

180 / 377

Free Cashflow

205 / 361

Performance 5 years

242 / 377

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.